199 related articles for article (PubMed ID: 28205194)
1. Novel and Expanded Oncology Drug Approvals of 2016-PART 2: New Options in the Management of Hematologic Malignancies.
Knepper TC; Saller J; Walko CM
Oncology (Williston Park); 2017 Feb; 31(2):138-46. PubMed ID: 28205194
[TBL] [Abstract][Full Text] [Related]
2. Novel and Expanded Oncology Drug Approvals of 2016-PART 1: New Options in Solid Tumor Management.
Knepper TC; Saller J; Walko CM
Oncology (Williston Park); 2017 Feb; 31(2):110-21. PubMed ID: 28205191
[TBL] [Abstract][Full Text] [Related]
3. Venetoclax: A novel B-cell lymphoma-2 inhibitor for chronic lymphocytic leukemia and other hematologic malignancies.
Olin JL; Griffiths CL; Smith MB
J Oncol Pharm Pract; 2018 Oct; 24(7):517-524. PubMed ID: 28696175
[TBL] [Abstract][Full Text] [Related]
4. Updates on Hematologic Malignancies in the Older Adult: Focus on Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Multiple Myeloma.
Huang LW; Wong SW; Andreadis C; Olin RL
Curr Oncol Rep; 2019 Mar; 21(4):35. PubMed ID: 30848394
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy for hematologic malignancies.
Kuriakose P
Cancer Control; 2005 Apr; 12(2):82-90. PubMed ID: 15855891
[TBL] [Abstract][Full Text] [Related]
6. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
Deckert J; Wetzel MC; Bartle LM; Skaletskaya A; Goldmacher VS; Vallée F; Zhou-Liu Q; Ferrari P; Pouzieux S; Lahoute C; Dumontet C; Plesa A; Chiron M; Lejeune P; Chittenden T; Park PU; Blanc V
Clin Cancer Res; 2014 Sep; 20(17):4574-83. PubMed ID: 24987056
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults.
Rao AV; Schmader K
Am J Geriatr Pharmacother; 2007 Sep; 5(3):247-62. PubMed ID: 17996665
[TBL] [Abstract][Full Text] [Related]
8. B-Cell Malignancies: The Use of Small Molecule Agents for Treatment and Management.
Rogers BB
Clin J Oncol Nurs; 2020 Apr; 24(2):199-204. PubMed ID: 32196006
[TBL] [Abstract][Full Text] [Related]
9. Meaningful endpoints for therapies approved for hematologic malignancies.
Smith BD; DeZern AE; Bastian AW; Durie BGM
Cancer; 2017 May; 123(10):1689-1694. PubMed ID: 28222220
[TBL] [Abstract][Full Text] [Related]
10. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Dennie TW; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
[TBL] [Abstract][Full Text] [Related]
11. Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies.
Gupta IV; Jewell RC
Ann N Y Acad Sci; 2012 Aug; 1263():43-56. PubMed ID: 22830942
[TBL] [Abstract][Full Text] [Related]
12. Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review.
Howard SC; Trifilio S; Gregory TK; Baxter N; McBride A
Ann Hematol; 2016 Mar; 95(4):563-73. PubMed ID: 26758269
[TBL] [Abstract][Full Text] [Related]
13. Bendamustine in the treatment of hematologic malignancies. Introduction.
Diehl V; Cheson BD
Semin Oncol; 2002 Aug; 29(4 Suppl 13):1-3. PubMed ID: 12170424
[No Abstract] [Full Text] [Related]
14. Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia.
Nightingale G
Ann Pharmacother; 2011 Oct; 45(10):1248-55. PubMed ID: 21896924
[TBL] [Abstract][Full Text] [Related]
15. Obinutuzumab for the treatment of chronic lymphocytic leukemia.
Rogers KA; Jones JA
Drugs Today (Barc); 2014 Jun; 50(6):407-19. PubMed ID: 24983589
[TBL] [Abstract][Full Text] [Related]
16. [Hematologic Malignancies/Pediatric Malignancies. Roles of Drugs Approved as New Agents and as Additional Indications for Relapse or Refractory Hematologic Malignancies].
Usui N
Gan To Kagaku Ryoho; 2016 May; 43(5):528-9. PubMed ID: 27344679
[No Abstract] [Full Text] [Related]
17. Combination therapy with the type II anti-CD20 antibody obinutuzumab.
Klein C; Bacac M; Umana P; Fingerle-Rowson G
Expert Opin Investig Drugs; 2017 Oct; 26(10):1145-1162. PubMed ID: 28845710
[TBL] [Abstract][Full Text] [Related]
18. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.
Kurtz SE; Eide CA; Kaempf A; Khanna V; Savage SL; Rofelty A; English I; Ho H; Pandya R; Bolosky WJ; Poon H; Deininger MW; Collins R; Swords RT; Watts J; Pollyea DA; Medeiros BC; Traer E; Tognon CE; Mori M; Druker BJ; Tyner JW
Proc Natl Acad Sci U S A; 2017 Sep; 114(36):E7554-E7563. PubMed ID: 28784769
[TBL] [Abstract][Full Text] [Related]
19. The 50th Annual Meeting of the American Society of Hematology.
Cunningham S; Muneer S
Clin Lymphoma Myeloma; 2009 Jun; 9(3):197-205. PubMed ID: 19525188
[No Abstract] [Full Text] [Related]
20. Balancing patient value and payer cost in hematologic malignancies: can it be done?
Allen PB; Flowers CR
Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):123-126. PubMed ID: 29486601
[No Abstract] [Full Text] [Related]
[Next] [New Search]
